Previous 10 | Next 10 |
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2023 financial results via press release before the market opens on Tuesday, November 7, 2023. About ...
U.S. BLA Filing in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (CRC) Planned for Midyear 2024 Potential Accelerated Filings for Advanced Pancreatic Cancer and Melanoma in 2025 Opportunity to Expand into Early-Stage Cancers Supported by Compelling Neoadjuvant CRC Data ...
Agenus Inc. (Nasdaq:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced expanded data from the company’s phase 1b study of botensilimab (BOT, multifunctional immune activator) in combination with balstilimab (BAL, anti-PD-1) in patients with a...
Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers today announced completion of the planned patient enrollment in ACTIVATE-Colorectal, a randomized Phase 2 trial in advanced colorectal cancer (CRC) evaluating the efficacy and safety of botensil...
2023-10-06 18:38:52 ET Summary AGEN has chosen to focus its efforts on botensilimab and balstilimab, postponing its other clinical and preclinical programs. A 25% workforce reduction and focus on its most promising pipeline members will help to save ~$40M in costs through the end ...
Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Company will host a corporate event to discuss advancements in its botensilimab/balstilimab (BOT/BAL) program at the upcoming European Society for Medical Oncology (ESM...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted, as of September 1, 2023 (“Grant Date”), inducement awards to...
2023-08-28 08:30:00 ET Growth stocks have lost momentum in August after a strong start to the year. The market is worried about the impact of a possible recession, high inflation, and high interest rates on the future earnings of companies. However, smart investors know that market downturn...
2023-08-23 08:35:23 ET More on Agenus Agenus: This Time May Be Different Agenus GAAP EPS of -$0.22 misses by $0.01, revenue of $22.9M misses by $0.63M Agenus wins FDA fast track tag for colorectal cancer therapy Agenus extends gains after Q4 2022 results ...
Strategic Prioritization to Deliver Savings of $40M Through End of 2023 Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources to accelerate the development, registration, and commercial...
News, Short Squeeze, Breakout and More Instantly...
Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilim...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a huma...
2024-06-27 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...